alexa Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Haematology

Haematology

Journal of Blood Disorders & Transfusion

Author(s): Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, , Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT,

Abstract Share this page

Abstract The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to > or =6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65\%: skin 17/20 (63\%), mouth 10/21 (48\%), eyes 6/14 (43\%), liver 3/12 (25\%), lung 3/8 (37.5\%), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n=3), disease relapse (n=1), infection (n=3), sudden death (n=1). The actuarial 2 year survival is currently 76\%. We confirm that Rituximab is effective in over 50\% of patients with refractory cGVHD and may have a beneficial impact on survival. This article was published in Bone Marrow Transplant and referenced in Journal of Blood Disorders & Transfusion

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords